Cited 23 times in
The long-term effects of rosiglitazone on serum lipid concentrations and body weight
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강은석 | - |
dc.contributor.author | 안철우 | - |
dc.contributor.author | 이현철 | - |
dc.contributor.author | 차봉수 | - |
dc.date.accessioned | 2015-06-10T12:06:57Z | - |
dc.date.available | 2015-06-10T12:06:57Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0300-0664 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/109217 | - |
dc.description.abstract | OBJECTIVE: Although rosiglitazone, an insulin sensitizer, is known to have beneficial effects on high density lipoprotein cholesterol (HDL-C) concentrations and low density lipoprotein (LDL) particle size, it has unwanted effects on total cholesterol (TC) and LDL cholesterol (LDL-C) concentrations and body weight in some short-term studies. The aim of this study was to evaluate the long-term effects of rosiglitazone on serum lipid levels and body weight. DESIGN: Open labelled clinical study. PATIENTS AND MEASUREMENTS: We prospectively evaluated fasting serum glucose, haemoglobin A(1c) (HbA(1c)), lipid profiles and body weight at baseline and every 3 months after the use of rosiglitazone (4 mg/day) for 18 months in 202 type 2 diabetic patients. RESULTS: TC levels increased maximally at 3 months and decreased thereafter. However, overall, TC levels remained significantly higher at 18 months than those at baseline. LDL-C levels from the 3-month to the 12-month timepoint were significantly higher than those at baseline. However, after 15 months, LDL-C concentrations were not significantly different from basal LDL-C concentrations. HDL-C levels increased after the first 3 months and these levels were maintained. The increment of change in HDL-C was more prominent in patients with low basal HDL-C concentrations than in patients with high basal HDL-C concentrations. Body weight increased after the first 3 months and these levels were maintained. CONCLUSIONS: HDL-C and body weight increased and remained elevated for the duration of the study. There was an initial increase in LDL-C but this attenuated and by the end of the study was not significantly elevated above baseline levels. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 453~459 | - |
dc.relation.isPartOf | CLINICAL ENDOCRINOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Blood Glucose/metabolism | - |
dc.subject.MESH | Body Mass Index | - |
dc.subject.MESH | Body Weight* | - |
dc.subject.MESH | Cholesterol/blood | - |
dc.subject.MESH | Cholesterol, HDL/blood | - |
dc.subject.MESH | Cholesterol, LDL/blood | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/blood | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/drug therapy* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glycated Hemoglobin A/analysis | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents/therapeutic use* | - |
dc.subject.MESH | Insulin/blood | - |
dc.subject.MESH | Lipids/blood* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Rosiglitazone | - |
dc.subject.MESH | Thiazolidinediones/therapeutic use* | - |
dc.subject.MESH | Time | - |
dc.subject.MESH | Triglycerides/blood | - |
dc.title | The long-term effects of rosiglitazone on serum lipid concentrations and body weight | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Wan Sub Shim | - |
dc.contributor.googleauthor | Mi Young Do | - |
dc.contributor.googleauthor | Soo Kyung Kim | - |
dc.contributor.googleauthor | Hae Jin Kim | - |
dc.contributor.googleauthor | Kyu Yeon Hur | - |
dc.contributor.googleauthor | Eun Seok Kang | - |
dc.contributor.googleauthor | Chul Woo Ahn | - |
dc.contributor.googleauthor | Sung Kil Lim | - |
dc.contributor.googleauthor | Hyun Chul Lee | - |
dc.contributor.googleauthor | Bong Soo Cha | - |
dc.identifier.doi | 10.1111/j.1365-2265.2006.02614.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00068 | - |
dc.contributor.localId | A02270 | - |
dc.contributor.localId | A03301 | - |
dc.contributor.localId | A03996 | - |
dc.relation.journalcode | J00571 | - |
dc.identifier.eissn | 1365-2265 | - |
dc.identifier.pmid | 16984237 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.2006.02614.x/abstract | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.alternativeName | Ahn, Chul Woo | - |
dc.contributor.alternativeName | Lee, Hyun Chul | - |
dc.contributor.alternativeName | Cha, Bong Soo | - |
dc.contributor.affiliatedAuthor | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | Ahn, Chul Woo | - |
dc.contributor.affiliatedAuthor | Lee, Hyun Chul | - |
dc.contributor.affiliatedAuthor | Cha, Bong Soo | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 65 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 453 | - |
dc.citation.endPage | 459 | - |
dc.identifier.bibliographicCitation | CLINICAL ENDOCRINOLOGY, Vol.65(4) : 453-459, 2006 | - |
dc.identifier.rimsid | 55766 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.